Lysosomal

formerly Lysosomal TherapeuticsAcquired

Lysosomal Therapeutics, Inc. (LTI)

United States · $24.8M raised

Business Model
B2B
Total Funding
$24.8M
Last Round
$20.0M Series AFeb 2015
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Lysosomal Therapeutics Inc. (LTI) is dedicated to innovative research and development in the field of neurodegeneration, leveraging the genetically and clinically validated link between lysosomal disorders and neurodegenerative diseases to build a novel drug discovery platform. LTI's lead program, LTI-291, is a first-in-class drug candidate targeting GBA-associated Parkinsonism (GBA-AP), addressing mutations in the GBA1 gene, the most common genetic risk factor for parkinsonism. The company is led by a team of scientists, clinical professionals, and business leaders with deep experience in genetic and neurodegenerative disease drug development.

Summary

Lysosomal is a Biotech company based in United States. It has raised $24.8M in total across 2 rounds, most recently a $20.0M Series A round in Feb 2015. Investors include Atlas Venture, Hatteras Venture Partners and Sanofi Ventures.

Tech & App Stack

1 technology or app tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries AFeb 2015
$20.0M

Sign up to see all 2 events

Funding: Seed through Series A. Amounts, valuations, and investors where available.

Investors

Similar Companies

ParexelAcquired

One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...

Raleigh, United States10001+Biotech
Private EquityTotal funding$5.0BJun 2017
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Lysosomal on Indexed.vc
<a href="https://indexed.vc/companies/lysosomal"><img src="https://indexed.vc/api/badge/company/lysosomal" alt="Lysosomal on Indexed.vc" width="260" height="76" /></a>